📰 Myeloma Program News
Page 4 - Myeloma Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Myeloma Program. Real-time updates on events, politics, business and more.
August 27, 2022
Data featured in plenary session at the 19th International Myeloma Society Annual Meeting LOS ANGELES, Aug. 27, 2022 /PRNewswire/ -- The Janssen P...
August 23, 2022
/PRNewswire/ -- K36 Therapeutics, Inc. ("K36"), a privately held biotechnology company developing novel targeted therapies for the unmet medical needs of...
December 21, 2021
Here’s a look back at the biggest stories at the University of Miami during the past year.
December 13, 2021
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today longer-term results from the Phase 1b/2 CARTITUDE-1 study evaluating...
December 12, 2021
Data presented at ASH 2021 congress show 83 percent of patients achieved a stringent complete response at median follow-up of 22 months1 92 percent of evaluable patients achieved minimal residual
December 12, 2021
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today longer-term results from the Phase 1b/2 CARTITUDE-1 study evaluating...
December 1, 2021
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX...
December 1, 2021
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX...
March 1, 2021
The FDA has approved melphalan flufenamide (Pepaxto; melflufen) for use in combination with dexamethasone to treat adult patients with relapsed or refractory multiple myeloma.
February 27, 2021
FDA approves Oncopeptides PEPAXTO ( melphalan flufenamide) for patients with relapsed or refractory multiple myeloma STOCKHOLM, Feb. 26, 2021 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO ), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announced that the U.S. Food and Drug Administration, FDA, has approved PEPAXTO (melphalan flufenamide, also known as melflufen), in combination with dexamethasone, for the...